17 recruiting, 6 active not recruiting, 6 terminated, 5 completed. 19 Phase 2, 9 Not applicable, 9 Phase 1, 8 Phase 3.
Follow Transurethral Resection of Bladder: new trials by email Literature Review of Transurethral Resection of Bladder trials Research Report on Transurethral Resection of Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer Alpha1H, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Chemotherapy - Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | Recruiting | Hamlet Pharma AB | 194 | 2026-09-17 | 2026-09-21 |
| Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer Trastuzumab Rezetecan, Adebrelimab, Concurrent Bladder Radiotherapy - Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | Tongji Hospital | 70 | 2026-09-01 | 2026-10-08 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 114 | 2026-08-01 | 2026-08-10 |
| A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer Bicalutamide, Biopsy Procedure, Biospecimen Collection - Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 | Recruiting | University of Wisconsin, Madison | 80 | 2026-06-25 | 2026-09-30 |
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-26 |
| Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors Ad-hCMV-Flt3L, Ad-hCMV-TK, Biospecimen Collection - Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 11 | 2026-05-22 | 2026-06-15 |
| DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma DOC1021, Tumor resection, pIFN (peginterferon alfa-2a) - Refractory Melanoma | Phase 1 / Phase 2 | Recruiting | Diakonos Oncology Corporation | 35 | 2026-04-06 | 2026-09-09 |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2025-11-25 | 2026-10-01 |
| Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), Circulating tumour DNA levels assessment - Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy | Phase 3 | Recruiting | University of Rome Tor Vergata | 92 | 2025-08-15 | 2025-07-24 |
| NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment Active Surveillance, Control arm - Definitive bladder treatment - Muscle-Invasive Bladder Carcinoma | Phase 2 / Phase 3 | Recruiting | Peter Black | 688 | 2025-07-28 | 2025-07-30 |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy BCG Solution, Biopsy of Bladder, Cystoscopy - Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 330 | 2025-07-17 | 2026-10-02 |
| PROMIS and Mobility Evaluation in Sarcoma Patients Surgery - Sarcoma, Giant Cell Tumor of Bone | Recruiting | University of Calgary | 800 | 2025-07-01 | 2025-11-13 | |
| Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT) - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 47 | 2025-03-31 | 2026-10-01 |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) DOC1021, Tumor resection, Temodar (Temozolomide) - Glioblastoma (GBM) | Phase 2 | Recruiting | Diakonos Oncology Corporation | 180 | 2025-03-17 | 2026-07-01 |
| Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer. Tumor resection - Estrogen Receptor Positive Breast Cancer | Not applicable | Enrolling by invitation | University Ghent | 36 | 2024-09-25 | 2025-08-29 |
| OUTCOMES of SIMULTANEOUS TRANSURETHRAL PROSTATE and BLADDER TUMOR RESECTION VERSUS TRANSURETHRAL BLADDER TUMOR RESECTION in BLADDER TUMOR with BLADDER PROSTATE HYPERPLASIA Transurethral Resection of Prostate (TURP), Transurethral Resection Of Bladder Tumor - Bladder Cancer Recurrence, BPH (Benign Prostatic Hyperplasia) | Not applicable | Active not recruiting | Allama Iqbal Medical College | 60 | 2024-08-15 | 2025-02-11 |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Ganglioneuroblastoma, Nodular, Neuroblastoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 478 | 2024-04-19 | 2026-10-27 |
| FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Head and Neck Squamous Cell Carcinoma | Phase 1 | Terminated | University of Southern California | 1 | 2024-04-01 | 2025-09-16 |
Showing 20 of 42. Sign in to see all of them.
Urinary Bladder Neoplasms (15) · Glioblastoma (7) · Brain Neoplasms (3) · Glioma (3) · Sarcoma (3) · Astrocytoma (2) · Melanoma (2) · Neoplasms (2) · Non-Muscle Invasive Bladder Neoplasms (2) · Pancreatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Alzheimer Disease (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Craniopharyngioma (1)
National Cancer Institute (NCI) (5) · Diakonos Oncology Corporation (2) · Jasper Gerritsen (2) · Abramson Cancer Center at Penn Medicine (1) · Allama Iqbal Medical College (1) · Alliance for Clinical Trials in Oncology (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Centre Leon Berard (1) · Columbia University (1) · Eben Rosenthal (1) · Egyptian Biomedical Research Network (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Fox Chase Cancer Center (1) · Hamlet Pharma AB (1) · Hospital Sirio-Libanes (1)
United States (27) · Belgium (3) · Canada (3) · China (3) · Germany (3) · Netherlands (2) · Puerto Rico (2) · Switzerland (2) · Australia (1) · Brazil (1) · Czechia (1) · Egypt (1) · France (1) · Guam (1) · Italy (1)
Jasper Gerritsen, MD PhD (2) · Andrea T Franson (1) · Daniel D. Lee, MD (1) · Eben Rosenthal, MD (1) · Edward M Messing (1) · Edward W. Greeno, MD (1) · Eugene Pietzak, MD (1) · Gordon Li, MD (1) · Haowen Jiang, Pro. (1) · Jacob Thomas, MD (1) · Jakob R Izbicki, MD, FACS (1) · Jinhai Fan, MD (1) · Lawrence H Schwartz, MD (1) · Leslie Ballas (1)
PMID 24906700, PMID 33607632, PMID 33660142, PMID 39260848, PMID 39680823, PMID 40343719, PMID 41959823, PMID 42567733, PMID 42821609
U10CA180888 (2), P30CA014089 (1), P30CA014520 (1), P30CA068485 (1), P30CA124435 (1), P30CA168524 (1), P50CA090949 (1), U10CA180821 (1), U10CA180886 (1), U54CA168512 (1), UG1CA242635 (1), UM1CA186691 (1)